Effect of Smeglutide Combined with Dapagliflozin on Obese Type 2 Diabe-tes and Its Influence on Insulin Resistance and Visceral Fat Index
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
维普
万方数据
目的 探讨司美格鲁肽联合达格列净治疗肥胖型2型糖尿病的效果及对胰岛素抵抗、内脏脂肪指数的影响.方法 选取2022年5月—2023年9月江苏大学附属澳洋医院收治的84例肥胖型2型糖尿病患者为研究对象,按治疗方法不同分为两组,各42例,对照组采取达格列净治疗,观察组采用司美格鲁肽联合达格列净治疗,比较两组血糖指标[空腹血糖(fasting plasma glucose,FPG)、餐后2 h血糖(2-hour postprandial plasma glucose,2 hPG)、糖化血红蛋白(glycated hemoglobin A1c,HbA1c)]、胰岛功能[空腹胰岛素(fasting insulin,FINS)、胰岛素抵抗指数(homeostasis model assessment of insulin resistance,HOMA-IR)、胰岛β细胞功能指数(homeostasis model assessment-β,HOMA-β)]、内脏脂肪指数[内脏脂肪面积(visceral fat area,VFA)、中国人内脏脂肪指数(Chinese visceral fat index,CVAI)].结果 治疗后,观察组FPG、2 hPG、HbA1c水平低于对照组,差异有统计学意义(P均<0.05).治疗后,观察组FINS、HOMA-IR低于对照组,HOMA-β高于对照组,差异有统计学意义(P均<0.05).治疗后,观察组CVAI、VFA指标低于对照组,差异有统计学意义(P均<0.05).结论 司美格鲁肽联合达格列净治疗肥胖型2型糖尿病的效果满意,可有效降低血糖与胰岛素抵抗水平,并能控制内脏脂肪指数.
Objective To investigate the effect of smeglutide combined with dapagliflozin in the treatment of obese type 2 diabetes and its influence on insulin resistance and visceral fat index.Methods A total of 84 obese patients with type 2 diabetes admitted to Aoyang Hospital Affiliated to Jiangsu University from May 2022 to September 2023 were selected as the study objects and divided into two groups according to different treatment methods,with 42 cases in each group.The control group was treated with dapagliflozin,while the observation group was treated with semaglu-tide combined with dapagliflozin.The blood glucose indexes[fasting plasma glucose(FPG),2-hour postprandial plasma glucose(2 hPG),glycated hemoglobin A1c(HbA1c)],islet function[fasting insulin(FINS),homeostasis model assessment of insulin resistance(HOMA-IR),homeostasis model assessment-β(HOMA-β)],visceral fat index[vis-ceral fat area(VFA),Chinese visceral fat index(CVAI)]were compared between the two groups.Results After treat-ment,the levels of FPG,2 hPG and HbA1c in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).After treatment,FINS and HOMA-IR in observation group were lower than control group,and HOMA-β were higher than control group,the differences were statistically signifi-cant(all P<0.05).After treatment,CVAI and VFA indexes in the observation group were lower than those in the con-trol group,and the differences were statistically significant(both P<0.05).Conclusion Smeglutide combined with dapagliflozin has a satisfactory effect in the treatment of obese type 2 diabetes,which can effectively reduce the level of blood glucose and insulin resistance,and also control visceral fat index.
SmeglutideDapagliflozinObese type 2 diabetesInsulin resistanceVisceral fat index
维普
万方数据
